{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:07:22Z","timestamp":1795176442273,"version":"4.10.3"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although the discovery of the critical role of \u03b1-synuclein (\u03b1-syn) in the pathogenesis of Parkinson\u2019s disease (PD) is now twenty-five years old, it still represents a milestone in PD research. Abnormal forms of \u03b1-syn trigger selective and progressive neuronal death through mitochondrial impairment, lysosomal dysfunction, and alteration of calcium homeostasis not only in PD but also in other \u03b1-syn-related neurodegenerative disorders such as dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, and REM sleep behavior disorder. Furthermore, \u03b1-syn-dependent early synaptic and plastic alterations and the underlying mechanisms preceding overt neurodegeneration have attracted great interest. In particular, the presence of early inflammation in experimental models and PD patients, occurring before deposition and spreading of \u03b1-syn, suggests a mechanistic link between inflammation and synaptic dysfunction. The knowledge of these early mechanisms is of seminal importance to support the research on reliable biomarkers to precociously identify the disease and possible disease-modifying therapies targeting \u03b1-syn. In this review, we will discuss these critical issues, providing a state of the art of the role of this protein in early PD and other synucleinopathies.<\/jats:p>","DOI":"10.1038\/s41419-023-05672-9","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T04:03:10Z","timestamp":1677643390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":893,"title":["Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0326-5509","authenticated-orcid":false,"given":"Paolo","family":"Calabresi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2493-6295","authenticated-orcid":false,"given":"Alessandro","family":"Mechelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Natale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Volpicelli-Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Di Lazzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Ghiglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"5672_CR1","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science. 1997;276:2045\u20137.","journal-title":"Science"},{"key":"5672_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u201340.","journal-title":"Nature"},{"key":"5672_CR3","doi-asserted-by":"publisher","unstructured":"Goldstein DS, Isonaka R, Lamotte G, Kaufmann H. Different phenoconversion pathways in pure autonomic failure with versus without Lewy bodies. Clin Auton Res. https:\/\/doi.org\/10.1007\/s10286-021-00829-y 2021.","DOI":"10.1007\/s10286-021-00829-y"},{"key":"5672_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology"},{"key":"5672_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneurol.2017.26","volume":"13","author":"F Krismer","year":"2017","unstructured":"Krismer F, Wenning GK. Multiple system atrophy: insights into a rare and debilitating movement disorder. Nat Rev Neurol. 2017;13:232\u201343.","journal-title":"Nat Rev Neurol"},{"key":"5672_CR6","doi-asserted-by":"publisher","unstructured":"Burr\u00e9 J, Sharma M, S\u00fcdhof TC. Cell biology and pathophysiology of \u03b1-synuclein. Cold Spring Harb Perspect Med. 2018;8. https:\/\/doi.org\/10.1101\/cshperspect.a024091.","DOI":"10.1101\/cshperspect.a024091"},{"key":"5672_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","volume":"477","author":"T Bartels","year":"2011","unstructured":"Bartels T, Choi JG, Selkoe DJ. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477:107\u201310.","journal-title":"Nature"},{"key":"5672_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4827","volume":"5","author":"G Fusco","year":"2014","unstructured":"Fusco G, De Simone A, Gopinath T, Vostrikov V, Vendruscolo M, Dobson CM, et al. Direct observation of the three regions in alpha-synuclein that determine its membrane-bound behaviour. Nat Commun. 2014;5:3827.","journal-title":"Nat Commun"},{"key":"5672_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jmb.2009.03.021","volume":"389","author":"K Vamvaca","year":"2009","unstructured":"Vamvaca K, Volles MJ, Lansbury PT Jr. The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J Mol Biol. 2009;389:413\u201324.","journal-title":"J Mol Biol"},{"key":"5672_CR10","doi-asserted-by":"publisher","first-page":"22680","DOI":"10.1074\/jbc.M101181200","volume":"276","author":"MS Nielsen","year":"2001","unstructured":"Nielsen MS, Vorum H, Lindersson E, Jensen PH. Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. J Biol Chem. 2001;276:22680\u20134.","journal-title":"J Biol Chem"},{"key":"5672_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03111-4","volume":"9","author":"J Lautenschlager","year":"2018","unstructured":"Lautenschlager J, Stephens AD, Fusco G, Strohl F, Curry N, Zacharopoulou M, et al. C-terminal calcium binding of alpha-synuclein modulates synaptic vesicle interaction. Nat Commun. 2018;9:712.","journal-title":"Nat Commun"},{"issue":"Pt 2","key":"5672_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/brain\/117.2.235","volume":"117","author":"MI Papp","year":"1994","unstructured":"Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain. 1994;117(Pt 2):235\u201343.","journal-title":"Brain"},{"key":"5672_CR13","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1084\/jem.20112457","volume":"209","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm VM, Zhang B, O\u2019Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012;209:975\u201386.","journal-title":"J Exp Med"},{"key":"5672_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/ana.24066","volume":"75","author":"A Recasens","year":"2014","unstructured":"Recasens A, Dehay B, Bove J, Carballo-Carbajal I, Dovero S, Perez-Villalba A, et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2014;75:351\u201362.","journal-title":"Ann Neurol"},{"key":"5672_CR15","doi-asserted-by":"publisher","first-page":"e11464.","DOI":"10.1371\/journal.pone.0011464","volume":"5","author":"A Kurz","year":"2010","unstructured":"Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, Bockhart V, et al. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One. 2010;5:e11464.","journal-title":"PLoS One"},{"key":"5672_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0079-6123(10)84005-1","volume":"184","author":"A Ulusoy","year":"2010","unstructured":"Ulusoy A, Decressac M, Kirik D, Bjorklund A. Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson\u2019s disease. Prog Brain Res. 2010;184:89\u2013111.","journal-title":"Prog Brain Res"},{"key":"5672_CR17","doi-asserted-by":"publisher","unstructured":"Kumari P, Ghosh D, Vanas A, Fleischmann Y, Wiegand T, Jeschke G, et al. Structural insights into alpha-synuclein monomer-fibril interactions. Proc Natl Acad Sci U S A. 2021;118. https:\/\/doi.org\/10.1073\/pnas.2012171118.","DOI":"10.1073\/pnas.2012171118"},{"key":"5672_CR18","doi-asserted-by":"publisher","first-page":"162.","DOI":"10.1038\/s41531-022-00423-7","volume":"8","author":"GS Virdi","year":"2022","unstructured":"Virdi GS, Choi ML, Evans JR, Yao Z, Athauda D, Strohbuecker S, et al. Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson\u2019s disease in midbrain dopaminergic neurons. NPJ Parkinsons Dis. 2022;8:162.","journal-title":"NPJ Parkinsons Dis"},{"key":"5672_CR19","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","volume":"8","author":"L Maroteaux","year":"1988","unstructured":"Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988;8:2804\u201315.","journal-title":"J Neurosci"},{"key":"5672_CR20","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1097\/WNR.0b013e3282f03db4","volume":"18","author":"WW Li","year":"2007","unstructured":"Li WW, Yang R, Guo JC, Ren HM, Zha XL, Cheng JS, et al. Localization of alpha-synuclein to mitochondria within midbrain of mice. Neuroreport. 2007;18:1543\u20136.","journal-title":"Neuroreport"},{"key":"5672_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbrc.2007.01.043","volume":"354","author":"JJ Hoozemans","year":"2007","unstructured":"Hoozemans JJ, van Haastert ES, Eikelenboom P, de Vos RA, Rozemuller JM, Scheper W. Activation of the unfolded protein response in Parkinson\u2019s disease. Biochem Biophys Res Commun. 2007;354:707\u201311.","journal-title":"Biochem Biophys Res Commun"},{"key":"5672_CR22","doi-asserted-by":"publisher","first-page":"48984","DOI":"10.1074\/jbc.M208194200","volume":"277","author":"N Gosavi","year":"2002","unstructured":"Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem. 2002;277:48984\u201392.","journal-title":"J Biol Chem"},{"key":"5672_CR23","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1523\/JNEUROSCI.3809-03.2004","volume":"24","author":"HJ Lee","year":"2004","unstructured":"Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci. 2004;24:1888\u201396.","journal-title":"J Neurosci"},{"key":"5672_CR24","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1126\/science.1195227","volume":"329","author":"J Burre","year":"2010","unstructured":"Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329:1663\u20137.","journal-title":"Science"},{"key":"5672_CR25","doi-asserted-by":"publisher","unstructured":"Shen H, Pirruccello M, De Camilli P SnapShot: membrane curvature sensors and generators. Cell. 2012;150:1300, e1-2. https:\/\/doi.org\/10.1016\/j.cell.2012.08.017.","DOI":"10.1016\/j.cell.2012.08.017"},{"key":"5672_CR26","doi-asserted-by":"publisher","first-page":"80.","DOI":"10.3389\/fnins.2018.00080","volume":"12","author":"JC Bridi","year":"2018","unstructured":"Bridi JC, Hirth F. Mechanisms of alpha-Synuclein Induced Synaptopathy in Parkinson\u2019s Disease. Front Neurosci. 2018;12:80.","journal-title":"Front Neurosci"},{"key":"5672_CR27","doi-asserted-by":"publisher","first-page":"11113","DOI":"10.1073\/pnas.1903049116","volume":"116","author":"J Sun","year":"2019","unstructured":"Sun J, Wang L, Bao H, Premi S, Das U, Chapman ER, et al. Functional cooperation of \u03b1-synuclein and VAMP2 in synaptic vesicle recycling. Proc Natl Acad Sci Usa 2019;116:11113\u20135.","journal-title":"Proc Natl Acad Sci Usa"},{"key":"5672_CR28","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1523\/JNEUROSCI.20-09-03214.2000","volume":"20","author":"DD Murphy","year":"2000","unstructured":"Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci. 2000;20:3214\u201320.","journal-title":"J Neurosci"},{"key":"5672_CR29","doi-asserted-by":"publisher","first-page":"11915","DOI":"10.1523\/JNEUROSCI.3821-06.2006","volume":"26","author":"KE Larsen","year":"2006","unstructured":"Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci. 2006;26:11915\u201322.","journal-title":"J Neurosci"},{"key":"5672_CR30","doi-asserted-by":"publisher","first-page":"9364","DOI":"10.1523\/JNEUROSCI.4787-13.2014","volume":"34","author":"KJ Vargas","year":"2014","unstructured":"Vargas KJ, Makani S, Davis T, Westphal CH, Castillo PE, Chandra SS. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci. 2014;34:9364\u201376.","journal-title":"J Neurosci"},{"key":"5672_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrn.2016.178","volume":"18","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017;18:101\u201313.","journal-title":"Nat Rev Neurosci"},{"key":"5672_CR32","doi-asserted-by":"publisher","first-page":"9.","DOI":"10.1186\/s13024-018-0241-0","volume":"13","author":"K Yamada","year":"2018","unstructured":"Yamada K, Iwatsubo T. Extracellular alpha-synuclein levels are regulated by neuronal activity. Mol Neurodegener. 2018;13:9.","journal-title":"Mol Neurodegener"},{"key":"5672_CR33","doi-asserted-by":"publisher","first-page":"42.","DOI":"10.3389\/fnmol.2014.00042","volume":"7","author":"S Tenreiro","year":"2014","unstructured":"Tenreiro S, Eckermann K, Outeiro TF. Protein phosphorylation in neurodegeneration: friend or foe. Front Mol Neurosci. 2014;7:42.","journal-title":"Front Mol Neurosci"},{"key":"5672_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","volume":"25","author":"A Abeliovich","year":"2000","unstructured":"Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000;25:239\u201352.","journal-title":"Neuron"},{"key":"5672_CR35","doi-asserted-by":"publisher","first-page":"29542","DOI":"10.1074\/jbc.M115.691592","volume":"290","author":"B Butler","year":"2015","unstructured":"Butler B, Saha K, Rana T, Becker JP, Sambo D, Davari P, et al. Dopamine transporter activity is modulated by alpha-synuclein. J Biol Chem. 2015;290:29542\u201354.","journal-title":"J Biol Chem"},{"key":"5672_CR36","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","volume":"287","author":"E Masliah","year":"2000","unstructured":"Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000;287:1265\u20139.","journal-title":"Science"},{"key":"5672_CR37","doi-asserted-by":"publisher","first-page":"10603","DOI":"10.1523\/JNEUROSCI.0608-14.2014","volume":"34","author":"G Ronzitti","year":"2014","unstructured":"Ronzitti G, Bucci G, Emanuele M, Leo D, Sotnikova TD, Mus LV, et al. Exogenous alpha-synuclein decreases raft partitioning of Cav2.2 channels inducing dopamine release. J Neurosci. 2014;34:10603\u201315.","journal-title":"J Neurosci"},{"key":"5672_CR38","doi-asserted-by":"publisher","first-page":"15414","DOI":"10.1523\/JNEUROSCI.4742-09.2009","volume":"29","author":"I Putzier","year":"2009","unstructured":"Putzier I, Kullmann PH, Horn JP, Levitan ES. Cav1.3 channel voltage dependence, not Ca2+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons. J Neurosci. 2009;29:15414\u20139.","journal-title":"J Neurosci"},{"key":"5672_CR39","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1113\/jphysiol.1993.sp019742","volume":"466","author":"S Nedergaard","year":"1993","unstructured":"Nedergaard S, Flatman JA, Engberg I. Nifedipine- and omega-conotoxin-sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones. J Physiol. 1993;466:727\u201347.","journal-title":"J Physiol"},{"key":"5672_CR40","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.bbabio.2009.05.011","volume":"1787","author":"RS Balaban","year":"2009","unstructured":"Balaban RS. The role of Ca(2+) signaling in the coordination of mitochondrial ATP production with cardiac work. Biochim Biophys Acta. 2009;1787:1334\u201341.","journal-title":"Biochim Biophys Acta"},{"key":"5672_CR41","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/mds.27823","volume":"34","author":"YC Wong","year":"2019","unstructured":"Wong YC, Luk K, Purtell K, Burke Nanni S, Stoessl AJ, Trudeau LE, et al. Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals. Mov Disord. 2019;34:1406\u201322.","journal-title":"Mov Disord"},{"key":"5672_CR42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/cne.20323","volume":"479","author":"T Gonzalez-Hernandez","year":"2004","unstructured":"Gonzalez-Hernandez T, Barroso-Chinea P, De La Cruz Muros I, Del Mar Perez-Delgado M, Rodriguez M. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. J Comp Neurol. 2004;479:198\u2013215.","journal-title":"J Comp Neurol"},{"key":"5672_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.brainres.2011.01.064","volume":"1382","author":"H Chadchankar","year":"2011","unstructured":"Chadchankar H, Ihalainen J, Tanila H, Yavich L. Decreased reuptake of dopamine in the dorsal striatum in the absence of alpha-synuclein. Brain Res. 2011;1382:37\u201344.","journal-title":"Brain Res"},{"key":"5672_CR44","doi-asserted-by":"publisher","first-page":"10510","DOI":"10.1523\/JNEUROSCI.1659-16.2016","volume":"36","author":"MH Ludtmann","year":"2016","unstructured":"Ludtmann MH, Angelova PR, Ninkina NN, Gandhi S, Buchman VL, Abramov AY. Monomeric alpha-synuclein exerts a physiological role on brain ATP synthase. J Neurosci. 2016;36:10510\u201321.","journal-title":"J Neurosci"},{"key":"5672_CR45","doi-asserted-by":"crossref","first-page":"342ra78.","DOI":"10.1126\/scitranslmed.aaf3634","volume":"8","author":"R Di Maio","year":"2016","unstructured":"Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, et al. alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson\u2019s disease. Sci Transl Med. 2016;8:342ra78.","journal-title":"Sci Transl Med"},{"key":"5672_CR46","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/j.bbagen.2014.02.013","volume":"1840","author":"N Plotegher","year":"2014","unstructured":"Plotegher N, Gratton E, Bubacco L. Number and Brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells. Biochim Biophys Acta. 2014;1840:2014\u201324.","journal-title":"Biochim Biophys Acta"},{"key":"5672_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04422-2","volume":"9","author":"MHR Ludtmann","year":"2018","unstructured":"Ludtmann MHR, Angelova PR, Horrocks MH, Choi ML, Rodrigues M, Baev AY, et al. alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson\u2019s disease. Nat Commun. 2018;9:2293.","journal-title":"Nat Commun"},{"key":"5672_CR48","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/sj.cdd.4401705","volume":"12","author":"Z Gu","year":"2005","unstructured":"Gu Z, Nakamura T, Yao D, Shi ZQ, Lipton SA. Nitrosative and oxidative stress links dysfunctional ubiquitination to Parkinson\u2019s disease. Cell Death Differ. 2005;12:1202\u20134.","journal-title":"Cell Death Differ"},{"key":"5672_CR49","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1126\/science.aam9080","volume":"357","author":"LF Burbulla","year":"2017","unstructured":"Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson\u2019s disease. Science. 2017;357:1255\u201361.","journal-title":"Science"},{"issue":"Pt 5","key":"5672_CR50","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283.","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees AJ. Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283\u2013301. https:\/\/doi.org\/10.1093\/brain\/114.5.2283.","journal-title":"Brain"},{"key":"5672_CR51","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","volume":"117","author":"TG Beach","year":"2009","unstructured":"Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009;117:613\u201334.","journal-title":"Acta Neuropathol"},{"key":"5672_CR52","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/mds.25135","volume":"27","author":"JP Bolam","year":"2012","unstructured":"Bolam JP, Pissadaki EK. Living on the edge with too many mouths to feed: why dopamine neurons die. Mov Disord. 2012;27:1478\u201383.","journal-title":"Mov Disord"},{"key":"5672_CR53","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41593-019-0457-5","volume":"22","author":"MX Henderson","year":"2019","unstructured":"Henderson MX, Cornblath EJ, Darwich A, Zhang B, Brown H, Gathagan RJ, et al. Spread of \u03b1-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. Nat Neurosci. 2019;22:1248\u201357.","journal-title":"Nat Neurosci"},{"key":"5672_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neuroimage.2017.12.050","volume":"190","author":"Y Zeighami","year":"2019","unstructured":"Zeighami Y, Fereshtehnejad SM, Dadar M, Collins DL, Postuma RB, Mi\u0161i\u0107 B, et al. A clinical-anatomical signature of Parkinson\u2019s disease identified with partial least squares and magnetic resonance imaging. Neuroimage. 2019;190:69\u201378.","journal-title":"Neuroimage"},{"key":"5672_CR55","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/brain\/awx118","volume":"140","author":"SM Fereshtehnejad","year":"2017","unstructured":"Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson\u2019s disease: biomarkers and longitudinal progression. Brain. 2017;140:1959\u201376.","journal-title":"Brain"},{"key":"5672_CR56","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1212\/01.wnl.0000306697.48738.b6","volume":"70","author":"J Zaccai","year":"2008","unstructured":"Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG. Mrc Cognitive Function ANS. Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort. Neurology. 2008;70:1042\u20138.","journal-title":"Neurology"},{"key":"5672_CR57","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1212\/WNL.0b013e318278fe32","volume":"79","author":"JM Milber","year":"2012","unstructured":"Milber JM, Noorigian JV, Morley JF, Petrovitch H, White L, Ross GW, et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology. 2012;79:2307\u201314.","journal-title":"Neurology"},{"issue":"Pt 11","key":"5672_CR58","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1093\/brain\/awh625","volume":"128","author":"CF Orr","year":"2005","unstructured":"Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson\u2019s disease. Brain. 2005;128(Pt 11):2665\u201374.","journal-title":"Brain"},{"key":"5672_CR59","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","volume":"8","author":"EC Hirsch","year":"2009","unstructured":"Hirsch EC, Hunot S. Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection. Lancet Neurol. 2009;8:382\u201397.","journal-title":"Lancet Neurol"},{"key":"5672_CR60","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","volume":"140","author":"CK Glass","year":"2010","unstructured":"Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918\u201334.","journal-title":"Cell"},{"key":"5672_CR61","doi-asserted-by":"publisher","first-page":"247.","DOI":"10.3389\/fncel.2018.00247","volume":"12","author":"SA Ferreira","year":"2018","unstructured":"Ferreira SA, Romero-Ramos M. Microglia response during parkinson\u2019s disease: alpha-synuclein intervention. Front Cell Neurosci. 2018;12:247.","journal-title":"Front Cell Neurosci"},{"key":"5672_CR62","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/glia.10148","volume":"40","author":"J Husemann","year":"2002","unstructured":"Husemann J, Loike JD, Anankov R, Febbraio M, Silverstein SC. Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia. 2002;40:195\u2013205.","journal-title":"Glia"},{"issue":"Pt B","key":"5672_CR63","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nbd.2017.04.004","volume":"109","author":"EM Rocha","year":"2018","unstructured":"Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson\u2019s disease. Neurobiol Dis. 2018;109(Pt B):249\u201357.","journal-title":"Neurobiol Dis"},{"key":"5672_CR64","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/ana.25557","volume":"86","author":"V Grozdanov","year":"2019","unstructured":"Grozdanov V, Bousset L, Hoffmeister M, Bliederhaeuser C, Meier C, Madiona K, et al. Increased Immune Activation by Pathologic alpha-Synuclein in Parkinson\u2019s Disease. Ann Neurol. 2019;86:593\u2013606.","journal-title":"Ann Neurol"},{"key":"5672_CR65","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ana.20682","volume":"58","author":"H Chen","year":"2005","unstructured":"Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson\u2019s disease. Ann Neurol. 2005;58:963\u20137.","journal-title":"Ann Neurol"},{"key":"5672_CR66","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/ng.642","volume":"42","author":"TH Hamza","year":"2010","unstructured":"Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson\u2019s disease. Nat Genet. 2010;42:781\u20135.","journal-title":"Nat Genet"},{"key":"5672_CR67","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cellimm.2018.02.011","volume":"327","author":"MN Karpenko","year":"2018","unstructured":"Karpenko MN, Vasilishina AA, Gromova EA, Muruzheva ZM. Miliukhina IV, Bernadotte A. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-alpha levels in CSF and serum in relation to the clinical diversity of Parkinson\u2019s disease. Cell Immunol. 2018;327:77\u201382.","journal-title":"Cell Immunol"},{"key":"5672_CR68","doi-asserted-by":"publisher","unstructured":"Marogianni C, Sokratous M, Dardiotis E, Hadjigeorgiou GM, Bogdanos D, Xiromerisiou G. Neurodegeneration and inflammation\u2014an interesting interplay in Parkinson\u2019s disease. Int J Mol Sci. 2020;21. https:\/\/doi.org\/10.3390\/ijms21228421.","DOI":"10.3390\/ijms21228421"},{"key":"5672_CR69","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712\u20136.","journal-title":"Science"},{"key":"5672_CR70","first-page":"182","volume":"119","author":"V Brochard","year":"2009","unstructured":"Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119:182\u201392.","journal-title":"J Clin Invest"},{"key":"5672_CR71","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.parkreldis.2005.07.005","volume":"11","author":"Y Baba","year":"2005","unstructured":"Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord. 2005;11:493\u20138.","journal-title":"Parkinsonism Relat Disord"},{"key":"5672_CR72","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11481-012-9402-z","volume":"7","author":"JA Saunders","year":"2012","unstructured":"Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM, Torres-Russotto DR, et al. CD4+ regulatory and effector\/memory T cell subsets profile motor dysfunction in Parkinson\u2019s disease. J Neuroimmune Pharm. 2012;7:927\u201338.","journal-title":"J Neuroimmune Pharm"},{"key":"5672_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15626-w","volume":"11","author":"CS Lindestam Arlehamn","year":"2020","unstructured":"Lindestam Arlehamn CS, Dhanwani R, Pham J, Kuan R, Frazier A, Rezende Dutra J, et al. alpha-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson\u2019s disease. Nat Commun. 2020;11:1875.","journal-title":"Nat Commun"},{"key":"5672_CR74","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature22815","volume":"546","author":"D Sulzer","year":"2017","unstructured":"Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, et al. T cells from patients with Parkinson\u2019s disease recognize alpha-synuclein peptides. Nature. 2017;546:656\u201361.","journal-title":"Nature"},{"key":"5672_CR75","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00401-019-01974-5","volume":"137","author":"X Li","year":"2019","unstructured":"Li X, Koudstaal W, Fletcher L, Costa M, van Winsen M, Siregar B, et al. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology. Acta Neuropathol. 2019;137:825\u201336.","journal-title":"Acta Neuropathol"},{"key":"5672_CR76","doi-asserted-by":"publisher","first-page":"105698.","DOI":"10.1016\/j.nbd.2022.105698","volume":"168","author":"J Amin","year":"2022","unstructured":"Amin J, Erskine D, Donaghy PC, Surendranathan A, Swann P, Kunicki AP, et al. Inflammation in dementia with Lewy bodies. Neurobiol Dis. 2022;168:105698.","journal-title":"Neurobiol Dis"},{"key":"5672_CR77","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/jnnp-2017-317134","volume":"89","author":"E King","year":"2018","unstructured":"King E, O\u2019Brien JT, Donaghy P, Morris C, Barnett N, Olsen K, et al. Peripheral inflammation in prodromal Alzheimer\u2019s and Lewy body dementias. J Neurol Neurosurg Psychiatry. 2018;89:339\u201345.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5672_CR78","first-page":"400","volume":"27","author":"L Salvesen","year":"2017","unstructured":"Salvesen L, Winge K, Brudek T, Agander TK, L\u00f8kkegaard A, Pakkenberg B. Neocortical neuronal loss in patients with multiple system atrophy: a stereological study. Cereb Cortex. 2017;27:400\u201310.","journal-title":"Cereb Cortex"},{"key":"5672_CR79","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/jnen\/nly035","volume":"77","author":"AP Kiely","year":"2018","unstructured":"Kiely AP, Murray CE, Foti SC, Benson BC, Courtney R, Strand C, et al. Immunohistochemical and molecular investigations show alteration in the inflammatory profile of multiple system atrophy brain. J Neuropathol Exp Neurol. 2018;77:598\u2013607.","journal-title":"J Neuropathol Exp Neurol"},{"key":"5672_CR80","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S1474-4422(17)30173-4","volume":"16","author":"MG Stokholm","year":"2017","unstructured":"Stokholm MG, Iranzo A, \u00d8stergaard K, Serradell M, Otto M, Svendsen KB, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol. 2017;16:789\u201396.","journal-title":"Lancet Neurol"},{"key":"5672_CR81","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/mds.27841","volume":"34","author":"R Kim","year":"2019","unstructured":"Kim R, Jun JS, Kim HJ, Jung KY, Shin YW, Yang TW, et al. Peripheral Blood Inflammatory Cytokines in Idiopathic REM Sleep Behavior Disorder. Mov Disord. 2019;34:1739\u201344.","journal-title":"Mov Disord"},{"key":"5672_CR82","doi-asserted-by":"publisher","unstructured":"Farmen K, Nissen SK, Stokholm MG, Iranzo A, \u00d8stergaard K, Serradell M, et al. Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. Proc Natl Acad Sci U S A. 2021;118. https:\/\/doi.org\/10.1073\/pnas.2020858118.","DOI":"10.1073\/pnas.2020858118"},{"key":"5672_CR83","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1001\/archneur.63.4.604","volume":"63","author":"Y Compta","year":"2006","unstructured":"Compta Y, Mart\u00ed MJ, Paredes P, Tolosa E. Pure autonomic failure with altered dopamine transporter imaging. Arch Neurol. 2006;63:604\u20135.","journal-title":"Arch Neurol"},{"key":"5672_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14189-9","volume":"11","author":"XJ Wang","year":"2020","unstructured":"Wang XJ, Ma MM, Zhou LB, Jiang XY, Hao MM, Teng RKF, et al. Autonomic ganglionic injection of \u03b1-synuclein fibrils as a model of pure autonomic failure \u03b1-synucleinopathy. Nat Commun. 2020;11:934.","journal-title":"Nat Commun"},{"key":"5672_CR85","doi-asserted-by":"publisher","first-page":"E4016","DOI":"10.1073\/pnas.1309143110","volume":"110","author":"S Janezic","year":"2013","unstructured":"Janezic S, Threlfell S, Dodson PD, Dowie MJ, Taylor TN, Potgieter D, et al. Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc Natl Acad Sci Usa 2013;110:E4016\u201325.","journal-title":"Proc Natl Acad Sci Usa"},{"issue":"Pt 8","key":"5672_CR86","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease. Brain. 2013;136(Pt 8):2419\u201331.","journal-title":"Brain"},{"issue":"Pt 11","key":"5672_CR87","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1093\/brain\/awr233","volume":"134","author":"R Nandhagopal","year":"2011","unstructured":"Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson\u2019s disease. Brain. 2011;134(Pt 11):3290\u20138.","journal-title":"Brain"},{"key":"5672_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06724-9","volume":"7","author":"JA Phan","year":"2017","unstructured":"Phan JA, Stokholm K, Zareba-Paslawska J, Jakobsen S, Vang K, Gjedde A, et al. Early synaptic dysfunction induced by alpha-synuclein in a rat model of Parkinson\u2019s disease. Sci Rep. 2017;7:6363.","journal-title":"Sci Rep"},{"key":"5672_CR89","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1073\/pnas.1200575109","volume":"109","author":"M Lundblad","year":"2012","unstructured":"Lundblad M, Decressac M, Mattsson B, Bjorklund A. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci USA. 2012;109:3213\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5672_CR90","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.nbd.2011.12.013","volume":"45","author":"M Decressac","year":"2012","unstructured":"Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis. 2012;45:939\u201353.","journal-title":"Neurobiol Dis"},{"key":"5672_CR91","doi-asserted-by":"publisher","first-page":"105229.","DOI":"10.1016\/j.nbd.2020.105229","volume":"149","author":"MB Thomsen","year":"2021","unstructured":"Thomsen MB, Ferreira SA, Schacht AC, Jacobsen J, Simonsen M, Betzer C, et al. PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats. Neurobiol Dis. 2021;149:105229.","journal-title":"Neurobiol Dis"},{"key":"5672_CR92","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.nbd.2016.12.008","volume":"105","author":"LA Volpicelli-Daley","year":"2017","unstructured":"Volpicelli-Daley LA. Effects of alpha-synuclein on axonal transport. Neurobiol Dis. 2017;105:321\u20137.","journal-title":"Neurobiol Dis"},{"issue":"Pt 7","key":"5672_CR93","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/brain\/aws133","volume":"135","author":"Y Chu","year":"2012","unstructured":"Chu Y, Morfini GA, Langhamer LB, He Y, Brady ST, Kordower JH. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson\u2019s disease. Brain. 2012;135(Pt 7):2058\u201373.","journal-title":"Brain"},{"key":"5672_CR94","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1523\/JNEUROSCI.5427-08.2009","volume":"29","author":"CY Chung","year":"2009","unstructured":"Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci. 2009;29:3365\u201373.","journal-title":"J Neurosci"},{"key":"5672_CR95","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1091\/mbc.e14-02-0741","volume":"25","author":"LA Volpicelli-Daley","year":"2014","unstructured":"Volpicelli-Daley LA, Gamble KL, Schultheiss CE, Riddle DM, West AB, Lee VM. Formation of alpha-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. Mol Biol Cell. 2014;25:4010\u201323.","journal-title":"Mol Biol Cell"},{"issue":"Pt 7","key":"5672_CR96","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/brain\/awq132","volume":"133","author":"P Garcia-Reitbock","year":"2010","unstructured":"Garcia-Reitbock P, Anichtchik O, Bellucci A, Iovino M, Ballini C, Fineberg E, et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson\u2019s disease. Brain. 2010;133(Pt 7):2032\u201344.","journal-title":"Brain"},{"key":"5672_CR97","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1073\/pnas.1100976108","volume":"108","author":"B Winner","year":"2011","unstructured":"Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA. 2011;108:4194\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5672_CR98","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tins.2007.03.001","volume":"30","author":"P Calabresi","year":"2007","unstructured":"Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 2007;30:211\u20139.","journal-title":"Trends Neurosci"},{"key":"5672_CR99","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/nn.3743","volume":"17","author":"P Calabresi","year":"2014","unstructured":"Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci. 2014;17:1022\u201330.","journal-title":"Nat Neurosci"},{"key":"5672_CR100","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S0166-2236(99)01501-5","volume":"23","author":"P Calabresi","year":"2000","unstructured":"Calabresi P, Centonze D, Gubellini P, Pisani A, Bernardi G. Acetylcholine-mediated modulation of striatal function. Trends Neurosci. 2000;23:120\u20136.","journal-title":"Trends Neurosci"},{"key":"5672_CR101","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.tins.2007.07.008","volume":"30","author":"A Pisani","year":"2007","unstructured":"Pisani A, Bernardi G, Ding J, Surmeier DJ. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007;30:545\u201353.","journal-title":"Trends Neurosci"},{"key":"5672_CR102","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neuron.2012.04.038","volume":"75","author":"S Threlfell","year":"2012","unstructured":"Threlfell S, Lalic T, Platt NJ, Jennings KA, Deisseroth K, Cragg SJ. Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron. 2012;75:58\u201364.","journal-title":"Neuron"},{"key":"5672_CR103","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.neuron.2010.06.017","volume":"67","author":"JB Ding","year":"2010","unstructured":"Ding JB, Guzman JN, Peterson JD, Goldberg JA, Surmeier DJ. Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron. 2010;67:294\u2013307.","journal-title":"Neuron"},{"key":"5672_CR104","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-neuro-061010-113641","volume":"34","author":"CR Gerfen","year":"2011","unstructured":"Gerfen CR, Surmeier DJ. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci. 2011;34:441\u201366.","journal-title":"Annu Rev Neurosci"},{"key":"5672_CR105","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.biopsych.2015.08.013","volume":"79","author":"A Tozzi","year":"2016","unstructured":"Tozzi A, de Iure A, Bagetta V, Tantucci M, Durante V, Quiroga-Varela A, et al. Alpha-synuclein produces early behavioral alterations via striatal cholinergic synaptic dysfunction by interacting with GluN2D N-methyl-D-aspartate receptor subunit. Biol Psychiatry. 2016;79:402\u201314.","journal-title":"Biol Psychiatry"},{"key":"5672_CR106","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/brain\/awz065","volume":"142","author":"V Durante","year":"2019","unstructured":"Durante V, de Iure A, Loffredo V, Vaikath N, De Risi M, Paciotti S, et al. Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. Brain. 2019;142:1365\u201385.","journal-title":"Brain"},{"key":"5672_CR107","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrn3504","volume":"14","author":"P Paoletti","year":"2013","unstructured":"Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013;14:383\u2013400.","journal-title":"Nat Rev Neurosci"},{"key":"5672_CR108","doi-asserted-by":"publisher","unstructured":"Tozzi A, Sciaccaluga M, Loffredo V, Megaro A, Ledonne A, Cardinale A, et al. Dopamine-dependent early synaptic and motor dysfunctions induced by \u03b1-synuclein in the nigrostriatal circuit. Brain. https:\/\/doi.org\/10.1093\/brain\/awab242. 2021.","DOI":"10.1093\/brain\/awab242"},{"key":"5672_CR109","doi-asserted-by":"publisher","first-page":"e12844.","DOI":"10.1111\/nan.12844","volume":"48","author":"Y Miki","year":"2022","unstructured":"Miki Y, Tanji K, Shinnai K, Tanaka MT, Altay F, Foti SC, et al. Pathological substrate of memory impairment in multiple system atrophy. Neuropathol Appl Neurobiol. 2022;48:e12844.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"5672_CR110","doi-asserted-by":"publisher","first-page":"286.","DOI":"10.3389\/fnins.2020.00286","volume":"14","author":"M Iba","year":"2020","unstructured":"Iba M, Kim C, Florio J, Mante M, Adame A, Rockenstein E, et al. Role of alterations in protein kinase p38gamma in the pathogenesis of the synaptic pathology in dementia with lewy bodies and alpha-synuclein transgenic models. Front Neurosci. 2020;14:286.","journal-title":"Front Neurosci"},{"key":"5672_CR111","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/mds.28617","volume":"36","author":"KB Andersen","year":"2021","unstructured":"Andersen KB, Hansen AK, Damholdt MF, Horsager J, Skjaerbaek C, Gottrup H, et al. Reduced synaptic density in patients with lewy body dementia: An [(11) C]UCB-J PET imaging study. Mov Disord. 2021;36:2057\u201365.","journal-title":"Mov Disord"},{"key":"5672_CR112","doi-asserted-by":"publisher","first-page":"7111","DOI":"10.1523\/JNEUROSCI.0347-11.2011","volume":"31","author":"PL Brooks","year":"2011","unstructured":"Brooks PL, Peever JH. Impaired GABA and glycine transmission triggers cardinal features of rapid eye movement sleep behavior disorder in mice. J Neurosci. 2011;31:7111\u201321.","journal-title":"J Neurosci"},{"key":"5672_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02761-0","volume":"9","author":"S Valencia Garcia","year":"2018","unstructured":"Valencia Garcia S, Brischoux F, Clement O, Libourel PA, Arthaud S, Lazarus M, et al. Ventromedial medulla inhibitory neuron inactivation induces REM sleep without atonia and REM sleep behavior disorder. Nat Commun. 2018;9:504.","journal-title":"Nat Commun"},{"key":"5672_CR114","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1002\/mds.26415.","volume":"30","author":"A Schrag","year":"2015","unstructured":"Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for nonmotor manifestations of Parkinson\u2019s disease. Mov Disord. 2015;30:1490\u2013504. https:\/\/doi.org\/10.1002\/mds.26415.","journal-title":"Mov Disord"},{"key":"5672_CR115","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, et al. CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol. 2019;18:573\u201386.","journal-title":"Lancet Neurol"},{"key":"5672_CR116","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/mds.27646","volume":"34","author":"UJ Kang","year":"2019","unstructured":"Kang UJ, Boehme AK, Fairfoul G, Shahnawaz M, Ma TC, Hutten SJ, et al. Comparative study of cerebrospinal fluid \u03b1-synuclein seeding aggregation assays for diagnosis of Parkinson\u2019s disease. Mov Disord. 2019;34:536\u201344.","journal-title":"Mov Disord"},{"key":"5672_CR117","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, et al. Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature. 2020;578:273\u20137.","journal-title":"Nature"},{"key":"5672_CR118","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1002\/mds.28639","volume":"36","author":"A Stuendl","year":"2021","unstructured":"Stuendl A, Kraus T, Chatterjee M, Zapke B, Sadowski B, Moebius W, et al. Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson\u2019s Disease. Mov Disord. 2021;36:2508\u201318.","journal-title":"Mov Disord"},{"key":"5672_CR119","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/brain\/awac115","volume":"145","author":"A Kluge","year":"2022","unstructured":"Kluge A, Bunk J, Schaeffer E, Drobny A, Xiang W, Knacke H, et al. Detection of neuron-derived pathological \u03b1-synuclein in blood. Brain. 2022;145:3058\u201371.","journal-title":"Brain"},{"key":"5672_CR120","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601.","journal-title":"Mov Disord"},{"key":"5672_CR121","doi-asserted-by":"publisher","first-page":"702639.","DOI":"10.3389\/fnagi.2021.702639","volume":"13","author":"U Ganguly","year":"2021","unstructured":"Ganguly U, Singh S, Pal S, Prasad S, Agrawal BK, Saini RV, et al. Alpha-Synuclein as a Biomarker of Parkinson\u2019s Disease: Good, but Not Good Enough. Front Aging Neurosci. 2021;13:702639.","journal-title":"Front Aging Neurosci"},{"key":"5672_CR122","doi-asserted-by":"publisher","first-page":"53.","DOI":"10.3389\/fnagi.2014.00053","volume":"6","author":"L Parnetti","year":"2014","unstructured":"Parnetti L, Farotti L, Eusebi P, Chiasserini D, De Carlo C, Giannandrea D, et al. Differential role of CSF alpha-synuclein species, tau, and A\u03b242 in Parkinson\u2019s Disease. Front Aging Neurosci. 2014;6:53.","journal-title":"Front Aging Neurosci"},{"key":"5672_CR123","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","volume":"19","author":"D Volc","year":"2020","unstructured":"Volc D, Poewe W, Kutzelnigg A, L\u00fchrs P, Thun-Hohenstein C, Schneeberger A, et al. Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020;19:591\u2013600.","journal-title":"Lancet Neurol"},{"key":"5672_CR124","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3233\/JPD-212594","volume":"11","author":"W Poewe","year":"2021","unstructured":"Poewe W, Volc D, Seppi K, Medori R, L\u00fchrs P, Kutzelnigg A, et al. Safety and tolerability of active immunotherapy targeting \u03b1-synuclein with PD03A in patients with early parkinson\u2019s disease: a randomized, placebo-controlled, phase 1 study. J Parkinsons Dis. 2021;11:1079\u201389.","journal-title":"J Parkinsons Dis"},{"key":"5672_CR125","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/mds.28218","volume":"35","author":"WG Meissner","year":"2020","unstructured":"Meissner WG, Traon AP, Foubert-Samier A, Galabova G, Galitzky M, Kutzelnigg A, et al. A phase 1 randomized trial of specific active \u03b1-synuclein immunotherapies PD01A and PD03A in multiple system atrophy. Mov Disord. 2020;35:1957\u201365.","journal-title":"Mov Disord"},{"key":"5672_CR126","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","volume":"32","author":"EJ Bae","year":"2012","unstructured":"Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, et al. Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission. J Neurosci. 2012;32:13454\u201369.","journal-title":"J Neurosci"},{"key":"5672_CR127","doi-asserted-by":"publisher","first-page":"e19338.","DOI":"10.1371\/journal.pone.0019338","volume":"6","author":"E Masliah","year":"2011","unstructured":"Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One. 2011;6:e19338.","journal-title":"PLoS One"},{"key":"5672_CR128","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mds.27534","volume":"34","author":"J Jankovic","year":"2019","unstructured":"Jankovic J. Pathogenesis-targeted therapeutic strategies in Parkinson\u2019s disease. Mov Disord. 2019;34:41\u20134.","journal-title":"Mov Disord"},{"key":"5672_CR129","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867.","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N. Engl J Med. 2022;387:421\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2202867.","journal-title":"N. Engl J Med"},{"key":"5672_CR130","unstructured":"Kalluri H, Zadikoff L, Rueter L, Graff O, Xiong H. Randomized, placebo-controlled single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of ABBV-0805, an anti-alpha-synuclein monoclonal antibody in healthy subjects [abstract]. Mov Disorder. 2021;36:S179."},{"key":"5672_CR131","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/mds.27738","volume":"34","author":"M Brys","year":"2019","unstructured":"Brys M, Fanning L, Hung S, Ellenbogen A, Penner N, Yang M, et al. Randomized phase I clinical trial of anti-\u03b1-synuclein antibody BIIB054. Mov Disord. 2019;34:1154\u201363.","journal-title":"Mov Disord"},{"key":"5672_CR132","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, et al. Trial of cinpanemab in early Parkinson\u2019s disease. N. Engl J Med. 2022;387:408\u201320.","journal-title":"N. Engl J Med"},{"key":"5672_CR133","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s10571-016-0454-0","volume":"37","author":"L Almandoz-Gil","year":"2017","unstructured":"Almandoz-Gil L, Lindstr\u00f6m V, Sigvardson J, Kahle PJ, Lannfelt L, Ingelsson M, et al. Mapping of surface-exposed epitopes of in vitro and in vivo aggregated species of alpha-synuclein. Cell Mol Neurobiol. 2017;37:1217\u201326.","journal-title":"Cell Mol Neurobiol"},{"key":"5672_CR134","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol. 2013;125:795\u2013813.","journal-title":"Acta Neuropathol"},{"key":"5672_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34490-9","volume":"8","author":"DL Price","year":"2018","unstructured":"Price DL, Koike MA, Khan A, Wrasidlo W, Rockenstein E, Masliah E, et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease. Sci Rep. 2018;8:16165.","journal-title":"Sci Rep"},{"key":"5672_CR136","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/mds.29170","volume":"37","author":"JW Smit","year":"2022","unstructured":"Smit JW, Basile P, Prato MK, Detalle L, Mathy FX, Schmidt A. et al. Phase 1\/1b studies of UCB0599, an oral inhibitor of \u03b1-synuclein misfolding, including a randomized study in Parkinson\u2019s disease. Mov Disord. 2022;37:2045\u20132056.","journal-title":"Mov Disord"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05672-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05672-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05672-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T20:21:37Z","timestamp":1701980497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05672-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":136,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["5672"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-05672-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"assertion":[{"value":"19 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PC received\/receives research support, speaker honoraria, and support to attend national and international conferences (not related to the present study) from: Abbvie, Bial, Bayer Schering, Biogen-Domp\u00e8, Biogen-Idec, Eisai, Lilly, Lundbeck, Lusofarmaco, Merck-Serono, Novartis, Sanofi-Genzyme, Teva, UCB Pharma, Zambon. The other authors reported no funding from any institution, including personal relationships, interests, grants, employment, affiliations, patents, inventions, honoraria, consultancies, royalties, stock options\/ownership, or expert testimony for the last 12 months biomedical financial interests or potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}